Please login to the form below

Not currently logged in
Email:
Password:

Krystexxa

This page shows the latest Krystexxa news and features for those working in and with pharma, biotech and healthcare.

Horizon swoops on Raptor to add rare disease products

Horizon swoops on Raptor to add rare disease products

In January it bought Crealta in a deal valued at $510m that brought in Krystexxa (pegloticase), an FDA-approved drug for chronic refractory gout.

Latest news

  • AZ moves a step closer to gout drug approval in US AZ moves a step closer to gout drug approval in US

    Another recent entrant into the market - Savient Pharmaceuticals - was unable to make headway with its Krystexxa (pegloticase) therapy and was forced to file for bankruptcy in 2013.

  • AZ files gout drug lesinurad in Europe AZ files gout drug lesinurad in Europe

    Another recent entrant into the gout market - Savient Pharmaceuticals - was forced to file for bankruptcy in 2013 after poor sales of its gout therapy Krystexxa (pegloticase).

  • Phase III data back AZ's gout drug Phase III data back AZ's gout drug

    On the other hand, another recent entrant into the market - Savient Pharmaceuticals - was forced to file for bankruptcy last year on lacklustre sales of its gout therapy Krystexxa (pegloticase).

  • Good news for AZ on gout candidate lesinurad Good news for AZ on gout candidate lesinurad

    Another company with high expectations - Savient Pharma - was forced to file for bankruptcy protection in October after sales of its gout treatment Krystexxa (pegloticase) remained stubbornly low despite being launched in ... 2011. Krystexxa's poor

  • Savient faces bankruptcy after Krystexxa sales disappoint Savient faces bankruptcy after Krystexxa sales disappoint

    The Chapter 11 filing is primarily down to continued disappointing sales of Savient's lead product, gout treatment Krystexxa (pegloticase), which has failed to pick up sufficient revenues since its launch ... Further, we are thankful to our dedicated

More from news
Approximately 2 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Deal Watch December 2015 Deal Watch December 2015

    575. Crealta. Horizon. Acquisition - company. Krystexxa marketed for treatment of chronic refractory gout.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics